Tirzepatide 10mg

Overview

Tirzepatide is a once-weekly injectable dual agonist peptide designed for research into glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor biology. As a unimolecular synthetic peptide with modifications enabling both receptor activation and extended pharmacokinetics, Tirzepatide serves as a powerful experimental tool for investigating incretin-based metabolic regulation, energy homeostasis, and cardiorenal physiology in controlled laboratory settings.

In experimental biology, Tirzepatide is utilized to explore synergistic mechanisms of dual incretin receptor co-activation across multiple organ systems. By simultaneously engaging GIP and GLP-1 receptor signaling pathways—targeting pancreatic beta-cell function, central appetite circuits, gastric motility, adipose metabolism, and vascular protection—this peptide enables comprehensive study of metabolic disease mechanisms, glycemic control, body weight regulation, and tissue-specific insulin sensitivity.

Molecular & Biochemical Properties

Peptide Name: Tirzepatide
Amino Acid Sequence: 39-amino-acid synthetic peptide based on native GIP with site-specific modifications
Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight: ~4,813 Da (unmodified peptide backbone)
Structural Modifications:

• C20 fatty diacid acyl chain (icosanedioic acid) conjugated via γ-glutamic acid-based linker at position 20 (Lys residue)
• Two amino acid substitutions (Ala²→Aib, Ser¹³→α-methylserine) to enhance receptor selectivity and proteolytic resistance

Receptor Binding Profile:

• GIP Receptor (GIPR): Near-native agonist potency
• GLP-1 Receptor (GLP-1R): ~20% potency relative to native GLP-1
• In vitro GIPR:GLP-1R potency ratio: ~5:1

Pharmacokinetic Features:

• Half-Life: ~5 days in preclinical models (due to albumin binding via fatty acid chain and DPP-4 resistance)
• Administration: Subcutaneous injection
• Stability: Lyophilized formulation ensures shelf stability; reconstituted solution stable under refrigeration

Research Applications

Tirzepatide is employed exclusively within laboratory research workflows to model and dissect dual incretin receptor biology. Common experimental applications include:

Metabolic & Endocrine Research:

• Glucose Homeostasis Models: Investigating glucose-dependent insulin secretion, beta-cell proliferation, and alpha-cell glucagon suppression in diabetes models
• Energy Balance Studies: Evaluating food intake suppression, energy expenditure, and adipose tissue remodeling (browning, lipolysis)
• Body Weight Regulation: Assessing dose-dependent weight reduction kinetics and lean mass preservation

Cardiovascular & Renal Biology:

• Cardiorenal Protection: Studying effects on albuminuria, endothelial function, blood pressure regulation, and vascular inflammation in metabolic disease models
• Atherosclerosis Models: Examining lipid metabolism, macrophage polarization, and plaque stability

Hepatic & Adipose Tissue Studies:

• MASLD/NASH Models: Investigating hepatic steatosis reduction, fibrosis markers, and liver enzyme normalization
• Adipocyte Biology: Exploring adipogenesis, insulin sensitivity, and inflammatory cytokine release

Gastrointestinal & Neural Signaling:

• Gastric Emptying Studies: Characterizing delayed gastric motility and nutrient absorption kinetics
• Central Appetite Regulation: Mapping hypothalamic and brainstem neural circuit activation (POMC/CART, NPY/AgRP pathways)

Incretin Pathway Synergy:

• Comparative studies versus selective GLP-1 agonists to elucidate additive or synergistic benefits of dual GIPR/GLP-1R activation

Mechanistic & Pathway Context

Research suggests that Tirzepatide's dual receptor agonism influences overlapping and complementary signaling networks:

Incretin Signaling Cascades:

• GIP Receptor Activation: Enhances insulin secretion in a glucose-dependent manner; promotes lipid storage in adipocytes under nutrient-replete conditions; may support beta-cell survival via PKA and Epac pathways
• GLP-1 Receptor Activation: Stimulates insulin release, suppresses glucagon secretion, delays gastric emptying, and activates central satiety circuits (arcuate nucleus, nucleus tractus solitarius)

Synergistic Metabolic Effects:

• Combined GIPR/GLP-1R activation produces superior glycemic control and weight loss compared to selective GLP-1 agonism in preclinical models
• GIP may counteract GLP-1-mediated lipolysis in certain contexts while enhancing insulin sensitivity and glucose disposal

Downstream Signaling Pathways:

• cAMP/PKA/CREB: Both receptors couple to Gαs, triggering cyclic AMP production and downstream transcriptional activity
• PI3K/Akt: Mediates beta-cell proliferation, survival signaling, and peripheral glucose uptake
• mTOR & AMPK modulation: Regulates cellular energy sensing and metabolic substrate utilization

Tissue-Specific Actions:

• Pancreas: Glucose-dependent insulin secretion, beta-cell proliferation, reduced apoptosis
• Brain: Anorexigenic signaling, neuroprotection, reward pathway modulation
• Liver: Reduced gluconeogenesis, improved hepatic insulin sensitivity, decreased lipid accumulation
• Adipose: Enhanced insulin sensitivity, browning of white adipose tissue, modulation of inflammatory tone
• Kidney: Reduced glomerular hyperfiltration, decreased albuminuria, improved renal hemodynamics

Summary of Preclinical Research Contexts

Glycemic Control:

• Rodent and non-human primate models demonstrate dose-dependent reductions in fasting glucose, postprandial glucose excursions, and HbA1c-equivalent markers

Body Weight & Composition:

• Significant weight loss observed in diet-induced obesity models, with preferential loss of fat mass and preservation of lean body mass
• Enhanced thermogenesis and energy expenditure documented via indirect calorimetry

Cardiometabolic Outcomes:

• Improved lipid profiles (reduced triglycerides, LDL-C; increased HDL-C in some models)
• Reduced systemic inflammation (lower IL-6, TNF-α, CRP markers)
• Cardioprotective effects in ischemia-reperfusion injury models

Hepatic Health:

• Reduced liver fat content, improved histological scores in NASH models
• Decreased markers of hepatocellular injury (ALT, AST normalization)

Formulation & Quality Verification

Tirzepatide is supplied as a sterile, lyophilized powder intended exclusively for controlled laboratory research use. The peptide is manufactured via solid-phase peptide synthesis (SPPS) with subsequent lipidation and purification steps to achieve the final acylated structure.

Quality Control:

• Identity Confirmation: High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS/MS)
• Purity Assessment: ≥98% by analytical HPLC
• Endotoxin Testing: <1.0 EU/mg
• Sterility Verification: Compliant with USP <71> standards for research-grade materials

Each batch includes a Certificate of Analysis (CoA) documenting molecular weight, purity, sequence integrity, and storage recommendations.

Research Use Only (RUO) Disclaimer

All products available on this website are supplied solely for in-vitro laboratory research purposes. In-vitro studies are conducted outside of living organisms under controlled experimental conditions.

These materials are not pharmaceuticals, drugs, or therapeutic agents and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) for the diagnosis, treatment, mitigation, or prevention of any disease or medical condition.

Tirzepatide is intended exclusively for use by qualified researchers in academic, biotechnology, or pharmaceutical research settings. It is not for human consumption, clinical use, or self-administration.

For research use only. Not for human or veterinary use.

All Tirzepatide research compounds supplied by P1 Peptides are produced using lyophilization — also known as freeze-drying or cryodesiccation — a specialized dehydration process widely employed in the manufacture of research-grade synthetic peptide materials.

During this process, the peptide solution is first frozen to subzero temperatures and then subjected to low vacuum pressure conditions, allowing frozen water content to sublimate directly from solid ice to vapor phase, bypassing the liquid phase entirely. The result is a dry, porous crystalline powder — commonly referred to as a lyophilized peptide cake — that retains full structural integrity while remaining shelf-stable under controlled storage conditions.

In its lyophilized form, Tirzepatide research compounds remain stable for up to 12–18 months when stored properly under recommended conditions prior to reconstitution.

Reconstitution

When research protocols require reconstitution, Tirzepatide is typically prepared using bacteriostatic water (0.9% benzyl alcohol) under controlled laboratory conditions. Once reconstituted, the peptide solution must be refrigerated at 2–8°C (36–46°F) to maintain compound stability. Reconstituted solutions are generally stable for up to 28–30 days when stored appropriately under refrigeration.

To preserve structural integrity of the reconstituted solution throughout the storage period, researchers should:

• Avoid exposure to direct light
• Minimize temperature fluctuations
• Store vials in an upright position under refrigeration
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter
• Do not freeze reconstituted solutions

All reconstitution procedures should be carried out in accordance with standard laboratory protocols applicable to synthetic peptide research materials.

Recommended Storage Guidelines

The following storage parameters are recommended to maintain compound integrity throughout the research lifecycle:

Short-Term Storage — Unopened Lyophilized Vials

• Upon Receipt — Store unopened vials under refrigeration at 2–8°C (36–46°F), protected from direct light
• Lyophilized Tirzepatide may tolerate brief ambient temperature exposure during transit; however prolonged storage above 8°C is not recommended to preserve maximum compound integrity
• Under refrigerated conditions, lyophilized vials remain stable for several months

Long-Term Storage — Unopened Lyophilized Vials

• Extended Storage (6–18 months or longer) — Freezing at −20°C (−4°F) or below is recommended
• Optimal Long-Term Preservation — Storage at −80°C (−112°F) provides maximum stability, minimizing peptide degradation, aggregation, and oxidative modification over extended periods
• Repeated freeze-thaw cycles should be avoided as temperature cycling may compromise structural integrity of the compound

Post-Reconstitution Storage

• Store reconstituted solutions upright under refrigeration at 2–8°C (36–46°F), away from direct light
• Do not freeze reconstituted solutions
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter

Additional Laboratory Guidance

For specific storage requirements applicable to this research compound, researchers should consult the Certificate of Analysis (CoA) provided with each batch, as well as applicable peer-reviewed literature and institutional laboratory protocols governing synthetic peptide handling and storage procedures.

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.